This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-28. (Cancelled)

29. (Currently Amended) A compound of formula



I

in which

D	is phenyl, pyrrolyl, furyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl or triazinyl, each of which is monosubstituted or polysubstituted by Hal,
X and X'	are H,
W	is $-[C(R^2)_2]_nCONR^2[C(R^2)_2]_n-$, $-[C(R^2)_2]_nNR^2CO[C(R^2)_2]_n-$, $-[C(R^2)_2]_nO[C(R^2)_2]_n-$, $-[C(R^2)_2]_nNR^2[C(R^2)_2]_n-$, $-[C(R^2)_2]_nO[C(R^2)_2]_nCONR^2[C(R^2)_2]_n-$, $-[C(R^2)_2]_nNR^2[C(R^2)_2]_nCONR^2[C(R^2)_2]_n-$, $-[C(R^2)_2]_nNR^2COO[C(R^2)_2]_n-$ or $-[C(R^2)_2]_nS(O)_m[C(R^2)_2]_nCONR^2[C(R^2)_2]_n-$,
R^2	is H, A or $-[C(R^1)_2]_n-Ar'$,
Ar'	is phenyl,
Y	is phenylene or piperidinediyl, each of which is unsubstituted or monosubstituted or disubstituted by A, Br, Cl or F,
T	is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2-oxopyrazin-1-yl, 2,5-dioxo-pyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl,

2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-hydroxy-6-oxopiperazin-1-yl, 2-azabicyclo[2.2.2]octan-3-on-2-yl, 2-methoxy-6-oxopiperazin-1-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-iminopiperidin-1-yl or 2-iminopyrrolidin-1-yl,

R^1 is H,

A is unbranched or branched alkyl having 1-10 carbon atoms, in which 1-7 H atoms are optionally replaced by F,

m is 0, 1 or 2, and

n is 0, 1 or 2~~,~~

~~or a pharmaceutically acceptable derivative or solvate thereof~~.

30. (Currently Amended) A compound according to Claim 29, which is 2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopyridin-1-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopyrrolidin-1-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(2-oxopyrrolidin-1-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopyrazin-1-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-iminopyrrolidin-1-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]acetamide,
2-(5-chlorothiophen-2-yl)-5-[4-(2-oxopiperidin-1-yl)phenoxymethyl]-1*H*-benzimidazole,
2-(5-chlorothiophen-2-yl)-5-[4-(2-oxopiperidin-1-yl)phenoxy]-1*H*-benzimidazole,
2-(5-chlorothiophen-2-yl)-5-[4-(2-oxopiperidin-1-yl)phenylamino]-1*H*-benzimidazole,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]valeramide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-phenylpropionamide,

2-[2-(4-chlorophenyl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(4-chlorophenyl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chloropyridin-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chloropyridin-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]valeramide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)benzyl]acetamide,

1-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]formamide,

N-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-4-(2-oxopiperidin-1-yl)benzamide,

N-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-ylmethyl]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]amine,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-ylamino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-sulfonyl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-sulfonyl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-sulfonyl]-*N*-[4-(2-oxopyridin-1-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-sulfonyl]-*N*-[4-(2-oxopiperidin-1-

yl)benzyl]acetamide,
3-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]propionamide,
3-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]propionamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopiperidin-1-yl)phenyl]acetamide,
2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-carboxamide-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]amide,
2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-carboxamide-*N*-[4-(3-oxomorpholin-4-yl)phenyl]amide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]valeramide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]acetamide,
N-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-ylmethyl]-4-(2-oxopiperidin-1-yl)benzamide,
2-[2-(5-bromothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,
2-[2-(5-bromothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopiperidin-1-yl)phenyl]acetamide,
2-[2-(5-bromothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopyridin-1-yl)phenyl]acetamide,
2-[2-(5-bromothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]acetamide,
2-[2-(5-bromothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]valeramide,

N-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-ylmethyl]-2-[4-(3-oxomorpholin-4-yl)phenyl]acetamide, or

N-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-2-[4-(3-oxomorpholin-4-yl)phenyl]acetamide~~,~~

~~or a pharmaceutically acceptable derivative or solvate thereof~~.

31. (Withdrawn) A process for preparing a compound according to claim 29, comprising

a) for the preparation of a compound of formula I in which W is $-[C(R^2)_2]_nCONR^2[C(R^2)_2]_n-$,

reacting a compound of formula II



II

II

in which

L is Cl, Br, I or a free or reactively functionally modified OH group,

and R^1, R^2, D, X, X' and n are as defined for the compound of formula I,

wherein any further OH and/or amino group present is protected,

with a compound of formula III

Z'-Y-T III

in which

Z' is $NHR^2[C(R^2)_2]_n-$,

and R^2, Y, T and n are as defined for the compound of formula I,
wherein any protecting group is subsequently removed,

b) and/or converting a radical T in a compound of formula I into another radical T and/or
converting a base or acid of the compound of formula I into one of its salts.

32. (Withdrawn) A method for inhibiting coagulation factor Xa, comprising administering to a subject in need thereof an effective amount of a compound according to claim 29.

33. (Withdrawn) A method for inhibiting coagulation factor VIIa, comprising administering to a subject in need thereof an effective amount of a compound according to claim 29.

34. (Previously Presented) A pharmaceutical composition, comprising a compound according to claim 29 and a pharmaceutically acceptable carrier.

35. (Previously Presented) A pharmaceutical composition according to claim 34, further comprising another pharmaceutically active compound other than the compound of formula I.

36. (Withdrawn) A method for treating thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, a tumor, a tumor disease or tumor metastases, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 34.

37 (Currently Amended) A set or ~~of~~ kit, comprising separate packs of

(a) a compound according to claim 29, and

(b) a further pharmaceutically active compound other than the compound of formula I.

38. (Withdrawn) A method for treating thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, a tumor, a tumor disease or tumor metastases, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 35.

39. (Withdrawn) A process according to claim 31, wherein converting a radical T in a compound of formula I into another radical T is achieved by converting a sulfanyl compound into an imino compound, or by removing an amino-protecting group.

40. (Previously Presented) A compound according to claim 29, which is an isolated stereoisomer of a compound of formula I.

41. (Previously Presented) A compound of formula I,



I

in which

D	is phenyl, pyrrolyl, furyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl or triazinyl, each of which is monosubstituted or polysubstituted by Hal,
X and X'	are H,
W	is $-[C(R^2)_2]_nCONR^2[C(R^2)_2]_n-$, $-[C(R^2)_2]_nNR^2CO[C(R^2)_2]_n-$, $-[C(R^2)_2]_nO[C(R^2)_2]_n-$, $-[C(R^2)_2]_nNR^2[C(R^2)_2]_n-$, $-[C(R^2)_2]_nO[C(R^2)_2]_nCONR^2[C(R^2)_2]_n-$, $-[C(R^2)_2]_nNR^2[C(R^2)_2]_nCONR^2[C(R^2)_2]_n-$, $-[C(R^2)_2]_nNR^2COO[C(R^2)_2]_n-$ or $-[C(R^2)_2]_nS(O)_m[C(R^2)_2]_nCONR^2[C(R^2)_2]_n-$,
R^2	is H, A or $-[C(R^1)_2]_n-Ar'$,

Ar'	is phenyl,
Y	is phenylene or piperidinediyl, each of which is unsubstituted or monosubstituted or disubstituted by A, Br, Cl or F,
T	is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2-oxopyrazin-1-yl, 2,5-dioxo-pyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-hydroxy-6-oxopiperazin-1-yl, 2-azabicyclo[2.2.2]octan-3-on-2-yl, 2-methoxy-6-oxopiperazin-1-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-iminopiperidin-1-yl or 2-iminopyrrolidin-1-yl,
R^1	is H,
A	is unbranched or branched alkyl having 1-10 carbon atoms, in which 1-7 H atoms are optionally replaced by F,
m	is 0, 1 or 2, and
n	is 0, 1 or 2,

or a pharmaceutically acceptable salt thereof.

42. (Previously Presented) A compound according to Claim 41, which is

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopyridin-1-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopyrrolidin-1-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(2-oxopyrrolidin-1-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopyrazin-1-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-iminopyrrolidin-1-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]acetamide,

2-(5-chlorothiophen-2-yl)-5-[4-(2-oxopiperidin-1-yl)phenoxymethyl]-1*H*-benzimidazole,

2-(5-chlorothiophen-2-yl)-5-[4-(2-oxopiperidin-1-yl)phenoxy]-1*H*-benzimidazole,

2-(5-chlorothiophen-2-yl)-5-[4-(2-oxopiperidin-1-yl)phenylamino]-1*H*-benzimidazole,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]valeramide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-phenylpropionamide,

2-[2-(4-chlorophenyl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(4-chlorophenyl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chloropyridin-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chloropyridin-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]valeramide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)benzyl]acetamide,

1-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]formamide,

N-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-4-(2-oxopiperidin-1-yl)benzamide,

N-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-ylmethyl]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]amine,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-ylamino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-sulfonyl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-sulfonyl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-sulfonyl]-*N*-[4-(2-oxopyridin-1-yl)phenyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-sulfonyl]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]acetamide,

3-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]propionamide,

3-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopiperidin-1-yl)phenyl]acetamide,

2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-carboxamide-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]amide,

2-(5-chlorothiophen-2-yl)-1*H*-benzimidazole-5-carboxamide-*N*-[4-(3-oxomorpholin-4-yl)phenyl]amide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]valeramide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]acetamide,

2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]acetamide,

N-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-ylmethyl]-4-(2-oxopiperidin-1-yl)benzamide,

2-[2-(5-bromothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[2-(5-bromothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopiperidin-1-yl)phenyl]acetamide,

2-[2-(5-bromothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopyridin-1-yl)phenyl]acetamide,

2-[2-(5-bromothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[4-(2-oxopiperidin-1-

yl)benzyl]acetamide,
2-[2-(5-bromothiophen-2-yl)-1*H*-benzimidazol-5-yl]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,
2-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yloxy]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]valeramide,
N-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-ylmethyl]-2-[4-(3-oxomorpholin-4-yl)phenyl]acetamide, or
N-[2-(5-chlorothiophen-2-yl)-1*H*-benzimidazol-5-yl]-2-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,
or a pharmaceutically acceptable salt thereof.

43. (Withdrawn) A method for inhibiting coagulation factor Xa, comprising administering to a subject in need thereof an effective amount of a compound according to claim 41.

44. (Withdrawn) A method for inhibiting coagulation factor VIIa, comprising administering to a subject in need thereof an effective amount of a compound according to claim 41.

45. (Withdrawn) A method for inhibiting coagulation factor Xa, comprising administering to a subject in need thereof an effective amount of a compound according to claim 42.

46. (Withdrawn) A method for inhibiting coagulation factor VIIa, comprising administering to a subject in need thereof an effective amount of a compound according to claim 42.

47. (Currently Amended) A pharmaceutical composition, comprising a compound according to claim 41 and a pharmaceutically acceptable carrier.

48. (Currently Amended) A pharmaceutical composition, comprising a compound according to claim 42 and a pharmaceutically acceptable carrier.

49. (Withdrawn) A method for treating thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, a tumor, a tumor disease or tumor metastases, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 47.

50. (Withdrawn) A method for treating thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, a tumor, a tumor disease or tumor metastases, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 48.

51. (Previously Presented) A compound according to claim 41, which is an isolated stereoisomer of a compound of formula I.